Organon & Co.
Organon & Co. (OGN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · OGN · as of Jun 8, 2026
Key Statistics
Explore Organon & Co. Data
ogn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 22.2%
The OGN analyst consensus is Hold, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $11.33, representing -15.19% downside from the current price of $13.36.
Competitors & Peers
ogn competitorsOGN
ALVO
AUPH
AVDL
GRDN
HRMYStock Performance
Full HistoryAbout Organon & Co.
Organon & Co. a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio compri…
what is organon & co. · ogn stock overview · organon & co. company profile · who is organon & co. ceo · ogn NYSE · organon & co. headquarters · organon & co. business segments
About Stock Overview & Key Data
Organon & Co. (OGN) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE since May 14, 2021. As of the latest trading session, OGN stock price is $13.36, with a market capitalization of $3.5B. The stock has returned +36.89% over the past 12 months and +86.33% year-to-date.
According to 9 Wall Street analysts, the consensus rating for Organon & Co. stock is Hold, with an average 12-month price target of $11.33. In fiscal year 2025, Organon & Co. reported revenue of $6.2B and net income of $187.0M. For detailed data — including Organon & Co. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Organon & Co. (OGN) stock price is $13.36. The stock is traded on NYSE under the ticker symbol OGN. The 52-week range is $5.69 – $13.48.